Evidence map›Paper›PMID 41117550›Full record

ArticleJournal of extracellular vesicles2025

Hybrid Extracellular Vesicles With Combined Functional Properties From Mesenchymal Stem Cells and Astrocytes for Targeted Neurodegenerative Disease Applications.

David Wang, Kaitlin Clark, Kyle C Rouen, Grace Baird, Tara N Polackal, Priyadarsini Kumar, Yofiel Wyle, Diana L Farmer, Randy P Carney, Aijun Wang

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David WangDepartment of Biomedical Engineering, University of California-Davis, Davis, California, USA.ORCID https://orcid.org/0000-0001-6274-9947
Kaitlin ClarkInstitute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, California, USA.
Kyle C RouenDepartment of Physiology and Membrane Biology, University of California-Davis, Davis, California, USA.
Grace BairdDepartment of Surgery, School of Medicine, University of California Davis, Sacramento, California, USA.
Tara N PolackalDepartment of Surgery, School of Medicine, University of California Davis, Sacramento, California, USA.
Priyadarsini KumarDepartment of Surgery, School of Medicine, University of California Davis, Sacramento, California, USA.
Yofiel WyleInstitute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, California, USA.
Diana L FarmerInstitute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, California, USA.
Randy P CarneyDepartment of Biomedical Engineering, University of California-Davis, Davis, California, USA.ORCID https://orcid.org/0000-0001-8193-1664
Aijun WangDepartment of Biomedical Engineering, University of California-Davis, Davis, California, USA.

Funding

Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida TherapyR01NS115860 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FARMER, DIANA LEE, WANG, AIJUN · 2020 to 2024
$2.5M
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biologyR01EB034279 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Randy Carney, Cheemeng Tan · 2023 to 2026
$2.5M
Homogenized, engineered extracellular vesicles for intracranial targetingR01EB033389 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Randy Carney, Aijun Wang · 2023 to 2026
$2.4M
Engineering an extracellular vesicle-based targeted regenerative nanotherapeutic for multiple sclerosisR01NS131538 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aijun Wang · 2024 to 2026
$1.4M
In Utero Treatment of Dup15q Syndrome Via Lipid Nanoparticle Based Gene EditingR01NS144390 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NIREN MURTHY, Jill Lynn Silverman · 2025 to 2026
$1.3M
Phinney - Orbitrap Fusion ETDS10OD021801 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PHINNEY, BRETT S · 2016 to 2016
$600k
NHLBI NIH HHS T32 HL086350NIBIB NIH HHS 1R01EB034279NIBIB NIH HHS 3R01EB033389NIBIB NIH HHS R01 EB033389NIBIB NIH HHS R01 EB034279NIH HHS S10 OD021801NINDS NIH HHS 1R01NS115860NINDS NIH HHS 1R01NS131538NINDS NIH HHS R01 NS115860NINDS NIH HHS R01 NS131538NINDS NIH HHS R01 NS144390
6 · The paper itself

Abstract

Extracellular vesicles (EVs) have been investigated as nanotherapeutics and drug delivery systems for a wide range of disease indications. However, translational application of EVs is challenging due to their physical heterogeneity and variation in functional potency. The current study generated a novel hybrid EV formulation by membrane fusion of mesenchymal stem/stromal cell-derived EVs with astrocyte-derived EVs and defined its physicochemical and functional properties. Both EV populations have translational potential for neurodegenerative disease applications-a disease area with limited treatment strategies due to its complex disease biology requiring multi-faceted therapeutic approaches. However, individual EV sources lack the full set of therapeutic properties needed for comprehensive treatment. Stem cell-derived EVs possess general neuroprotective and anti-inflammatory effects but lack widespread blood-brain barrier penetration and specific neurodegenerative pathology targeting. Astrocytes are uniquely involved in key neuronal processes but are prone to adopting neuroinflammatory phenotypes in disease states. Using super resolution microscopy and quantitative proteomic analysis, we characterized, optimized, and validated a hybrid EV formulation for its brain cell targeting, neuroprotective function, and immunomodulatory capability. These results establish a platform for EV engineering through EV-EV hybridization and demonstrate the potential of one formulation for neurodegenerative applications.

Indexed as

AstrocytesExtracellular VesiclesMesenchymal Stem CellsNeurodegenerative DiseasesAnimalsBlood-Brain BarrierHumansastrocytehybrid extracellular vesiclemesenchymal stem cellquantitative proteomicssuper resolution microscopy

Identifiers

PMID41117550
PMCPMC12538816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.